Bonviva provides more treatment opportunity in patients with osteoporosis

Once-monthly Bonviva (ibandronate) has comparable efficacy to other bisphosphonates in a diverse population of patients in clinical settings and clinicians will have a greater awareness of patient compliance with Bonviva therapy, according to Professor Jonathan D. Adachi, Depart of Medicine of McMaster University in Canada.

In a recent symposium organized by GlaxoSmithKline, Adachi said that...